New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:08 EDTHALO, RHHBYRoche filing triggers $4M milestone payment to Halozyme
Halozyme Therapeutics (HALO) announced that Roche (RHHBY) has submitted a line extension application to the European Medicines Agency for a subcutaneous, SC, formulation of MabTheraŽ (rituxumab). The filing of the application triggered a $4M milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche.
News For HALO;RHHBY From The Last 14 Days
Check below for free stories on HALO;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:00 EDTHALOBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Subscribe for More Information
12:39 EDTHALOFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
Subscribe for More Information
07:10 EDTHALOFDA Blood Products Advisory Committee to hold a meeting
Subscribe for More Information
July 29, 2014
09:09 EDTRHHBYRoche to hold an investor update
Subscribe for More Information
08:15 EDTRHHBYEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Subscribe for More Information
05:58 EDTRHHBYExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use